- Home
- NTCT vs PHVS Comparison
NTCT vs PHVS Comparison
Compare NTCT & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTCT
- PHVS
- Stock Information
- Founded
- NTCT 1984
- PHVS 2015
- Country
- NTCT United States
- PHVS Switzerland
- Employees
- NTCT N/A
- PHVS N/A
- Industry
- NTCT EDP Services
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- NTCT Technology
- PHVS Health Care
- Exchange
- NTCT Nasdaq
- PHVS Nasdaq
- Market Cap
- NTCT 1.6B
- PHVS 1.3B
- IPO Year
- NTCT 1999
- PHVS 2021
- Fundamental
- Price
- NTCT $22.41
- PHVS $22.30
- Analyst Decision
- NTCT Hold
- PHVS Buy
- Analyst Count
- NTCT 1
- PHVS 6
- Target Price
- NTCT $25.00
- PHVS $36.67
- AVG Volume (30 Days)
- NTCT 676.1K
- PHVS 199.6K
- Earning Date
- NTCT 08-07-2025
- PHVS 08-12-2025
- Dividend Yield
- NTCT N/A
- PHVS N/A
- EPS Growth
- NTCT N/A
- PHVS N/A
- EPS
- NTCT 1.02
- PHVS N/A
- Revenue
- NTCT $834,861,000.00
- PHVS N/A
- Revenue This Year
- NTCT $3.89
- PHVS N/A
- Revenue Next Year
- NTCT $2.40
- PHVS N/A
- P/E Ratio
- NTCT $22.08
- PHVS N/A
- Revenue Growth
- NTCT 5.29
- PHVS N/A
- 52 Week Low
- NTCT $18.12
- PHVS $11.51
- 52 Week High
- NTCT $27.89
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- NTCT 50.81
- PHVS 58.68
- Support Level
- NTCT $22.21
- PHVS $19.56
- Resistance Level
- NTCT $23.20
- PHVS $22.30
- Average True Range (ATR)
- NTCT 0.66
- PHVS 1.31
- MACD
- NTCT 0.18
- PHVS 0.09
- Stochastic Oscillator
- NTCT 71.89
- PHVS 68.96
About NTCT NetScout Systems Inc.
NetScout Systems Inc is a provider of service assurance and cybersecurity solutions to enterprise and government networks. It bases its solutions on proprietary adaptive service intelligence technology, which helps customers monitor and identify performance issues and provides insight into network-based security threats. These solutions also deliver real-time and historical information, which provides insight to restore service and understand the quality of user experience. The company derives revenue from the sale of network management tools and security solutions. Its geographical regions include USA, which derives maximum revenue, Europe, Asia, and Rest of the World.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.